Pfizer’s R&D Reset Isn’t a Strategy — It’s a Symptom of Something Bigger
Chris Boshoff's public pivot toward oncology and obesity signals more than a pipeline refresh at Pfizer. Three converging moves...
R&D Portfolio
Chris Boshoff's public pivot toward oncology and obesity signals more than a pipeline refresh at Pfizer. Three converging moves...